SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-019754
Filing Date
2024-02-26
Accepted
2024-02-26 08:30:56
Documents
14
Period of Report
2024-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cogt-20240226.htm   iXBRL 8-K 56776
2 EX-99.1 cogt-ex99_1.htm EX-99.1 134346
3 GRAPHIC img214414700_0.jpg GRAPHIC 78289
  Complete submission text file 0000950170-24-019754.txt   431043

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cogt-20240226.xsd EX-101.SCH 28710
15 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20240226_htm.xml XML 4697
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 24673653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)